Retinoid signals and Th17-mediated pathology

Japanese Journal of Clinical Immunology

Volumn 32, Issue 1, 2009, Pages 20-28

  Klemann, Christian ^a   Je Raveney, Benjamin ^a   Oki, Shinji ^a   Yakamura, Takashi ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

AM80; ATRA; EAE; Foxp3; IL 10; IL 17; Retinoids; ROR t; Th17; Treg

Indexed keywords

11 CIS RETINAL; ALITRETINOIN; BEXAROTENE; CYTOKINE; ETRETIN; ETRETINATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; ISOTRETINOIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL; TAMIBAROTENE; TAZAROTENE; TRANSCRIPTION FACTOR FOXP3;

ACNE; ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DRUG HALF LIFE; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; KAPOSI SARCOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; METABOLITE; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PSORIASIS; RECOMMENDED DRUG DOSE; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL; UPREGULATION;

HUMANS; RETINOIDS; TH1 CELLS;

EID: 70350766629     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.32.20     Document Type: Review

References (72)

1. Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu Rev Immunol 7: 145-173, 1989.
2. Cher DJ, Mosmann TR: Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones, J Immunol. 138: 3688-3694, 1987.
3. Lassmann H, Ransohoff RM: The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal, Trends Immunol. 25: 132-137, 2004.
4. Gold R, Linington C, Lassmann H: Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research, Brain 129: 1953-1971, 2006.
5. Kuchroo VK, Anderson AC. Waldner H, Munder M, Bettelli E, Nicholson LB: T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire, Annu Rev Immunol 20: 101-123, 2002.
6. Billiau A, Heremans H, Vandekerckhove F, Dijkmans R, Sobis H, Meulepas E, Carton H: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma, J Immunol. 140: 1506-1510, 1988.
7. Voorthuis JA, Uitdehaag BM, De Groot CJ, Goede PH, van der Meide PH, Dijkstra CD: Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats, Clin Exp Immunol. 81: 183-188, 1990.
8. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, Dalton D, Fathman CG: Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE), J Immunol 156: 5-7, 1996.
9. Jacob CO, Holoshitz J, Van der Meide P, Strober S, McDevitt HO: Heterogeneous effects of IFN-gamma in adjuvant arthritis, J Immunol. 142: 1500-1505, 1989.
10. McGeachy MJ, Cua DJ: The link between IL-23 and Th17 cell-mediated immune pathologies, Semin Immunol 19: 372-376, 2007.
11. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature 421: 744-748, 2003.
12. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ: Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis, J Clin Invest 116: 1317-1326, 2006.
13. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature 441: 235-238, 2006.
14. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R: Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis, Cell Immunol 237: 123-130, 2005.
15. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med 201: 233-240, 2005.
16. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis, J Immunol 177: 566-573, 2006.
17. Rark H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineagt of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nat Immunol 6: 1133-1141, 2005.
18. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction, J Exp Med 203: 2673-2682, 2006.
19. Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein, Arthritis Rheum 46: 802-805, 2002.
20. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice, J Immunol 171: 6173-6177, 2003.
21. Bettelli E, Kuchroo VK: IL-1 2- and IL-23-induced. T helper cell subsets: birds of the same feather flock together, J Exp Med. 201: 169-171, 2005.
22. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17, J Biol Chem 278: 1910-1914, 2003.
23. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, Immunity 24: 179-189, 2006.
24. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T (H) 17 lineage, Nature 441: 231-234, 2006.
25. Ziegler SF: FOXP3: of mice and men, Annu Rev Immunol. 24: 209-226, 2006.
26. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR: The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory JL-17 + T helper cells, Cell 126: 1121-1133, 2006.
27. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, Ma L, Shah B, Panopoulos AD, Schluns KS, Watowich SS, Tian Q, Jetten AM, Dong C: T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma, Immunity 28: 29-39, 2008.
28. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB, Meylan F, Siegel R, Hennighausen L, Shevach EM, O'Shea J J: Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity 26: 371-381, 2007.
29. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C: STAT3 regulates cytokine-mediated generation of inflammatory helper T cells, J Biol Chem 282: 9358-9363, 2007.
30. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat Med 8: 500-508, 2002.
31. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H: Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis, Mult Scler 5: 101-104, 1999.
32. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L: Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am J Pathol 172: 146-155, 2008.
33. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD: Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes, J Invest Dermatol 111: 645-649, 1998.
34. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC: Interleukin-17 in inflammatory skin disorders, Curr Opin Allergy Clin Immunol 7: 374-381, 2007.
35. Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells, J Immunol 162: 1246-1251, 1999.
36. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, Science 314: 1461-1463, 2006.
37. Chambon P: A decade of molecular biology of retinoic acid receptors, Faseb J 10: 940-954, 1996.
38. Mark M, Ghyselinck NB, Chambon P: Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis, Annu Rev Pharmacol Toxicol 46: 451-480, 2006.
39. Stephensen CB: Vitamin A, infection, and immune function, Annu Rev Nutr 21: 167-192, 2001.
40. USDA: Composition of Foods Raw, Processed, Prepared USDA National Nutrient Database for Standard Reference, 2008.
41. Napoli JL: Retinoic acid: its biosynthesis and metabolism, Prog Nucleic Acid Res Mol Biol 63: 139-188, 1999.
42. Duester G: Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid, Eur J Biochem 267: 4315-4324, 2000.
43. Bourguet W, Germain P, Gronemeyer H: Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications, Trends Pharmacol Sci 21: 381-388, 2000.
44. Fukasawa H, Kagechika H, Shudo K: [Retinoid therapy for autoimmune diseases], Nihon Rinsho Meneki Gakkai Kaishi. 29: 114-126, 2006.
45. Fenaux P, Chomienne C, Degos L: Treatment of acute promyelocytic leukaemia, Best Pract Res Clin Haematol 14: 153-174, 2001.
46. Virown SE: Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms, Hematol Oncol Clin North Am 17: 763-783, 2003.
47. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takiuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R: Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid, Blood. 90: 967-973, 1997.
48. Kuenzli S, Saurat JH: Retinoids for the treatment of psoriasis: outrook for the future, Curr Opin Investig Drugs 2: 6251-630, 2001.
49. Massacesi L, Abbamondi AL, Giorgi C, Sarlo F, Lolli F, Amaducci L: Suppression of experimental allergic encephalomyelitis by retinoic acid, J Neurol Sci 80: 55-64, 1987.
50. Nozaki Y, Yamagata T, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M: Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis, Clin Immunol 119: 272-279, 2006.
51. Osanai M, Nishikiori N, Murata M, Chiba H, Kojima T, Sawada N: Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha agonists in colitis, Mol Pharmacol 71: 250-258, 2007.
52. Perez de Lema G, Lucio-Cazana FJ, Molina A, Luckow B, Schmid H, de Wit C, Moreno-Manzano V, Banas B, Mampaso F, Schlondorff D: Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease, Kidney Int 66: 1018-1028, 2004.
53. Zunino SJ, Storms DH, Stephensen CB: Diets rich in polyphenols and vitamin A inhibit the development of type I autoimmune diabetes in nonobese diabetic mice, J Nutr 137: 1216-1221, 2007.
54. Beehler BC, Brinckerhoff CE, Ostrowski J: Selective retinoic acid receptor ligands for rheumatoid artnritis, Curr Opin Investig Drugs 5: 1153-1157, 2004.
55. Iwata M, Eshima Y, Kagechika H: Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors, Int Immunol 15: 1017-1025, 2003.
56. Steinman L: A brief history of T (H) 17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage, Nat Med 13: 139-145, 2007.
57. Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, O'Shea JJ: Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway, Blood 111: 1013-1020, 2008.
58. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, Cheroutre H: Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid, Science 317: 256-260, 2007.
59. Schambach F, Schupp M, Lazar MA, Reiner SL: Activation of retinoic acid receptor-alpha favours regulatory T cell induction at the expense of IL-17-secreting T helper cell differentiation, Eur J Immunol 37: 2396-2399, 2007.
60. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, McFarlin DE, Scott DE: Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course, J Immunol 154: 450-458, 1995.
61. + regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression, J Immunol 181: 2277-2284, 2008.
62. Thaci D: Long-term data in the treatment of psoriasis, Br J Dermatol 159 Suppl 2: 18-24, 2008.
63. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3, Nat Genet 27: 20-21, 2001.
64. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse, Nat Genet 27: 68-73, 2001.
65. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy, Nat Genet 27: 18-20, 2001.
66. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ: All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation, J Exp Med 204: 1765-1774, 2007.
67. + regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism, J Exp Med 204: 1757-1764, 2007.
68. + regulatory T cells, J Immunol 179: 3724-3733, 2007.
69. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y: Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid, J Exp Med 204: 1775-1785, 2007.
70. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY: Retinoic acid imprints gut-homing specificity on T cells, Immunity 21: 527-538, 2004.
71. + T cells, J Exp Med 205: 1381-1393, 2008.
72. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ: TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T (H)-17 cell-mediated pathology, Nat Immunol 8: 1390-1397, 2007.